

STEINMETZ MICHAEL  
Form 4  
September 04, 2013

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Clarus Lifesciences I, L.P.

2. Issuer Name and Ticker or Trading Symbol  
GLOBUS MEDICAL INC [GMED]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)

(Last) (First) (Middle)  
C/O CLARUS VENTURES,  
LLC, 101 MAIN STREET, SUITE  
1210  
  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
09/03/2013

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |  |
| Class A Common Stock            | 09/03/2013                           |  | J <sup>(1)</sup>               |   | 7,244,201   | D  | \$ 0 0                                     |
|                                 |                                      |  |                                |   |   |  | By Fund <u>(2)</u>                         |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: STEINMETZ MICHAEL - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Following Transaction (Instr. 6) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       | Title                       | Amount or Number of Shares |
|--|---------------|-----------|---------|-------|-----------------------------|----------------------------|
|  | Director      | 10% Owner | Officer | Other |                             |                            |
| Clarus Lifesciences I, L.P.<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142        |               | X         |         |       |                             |                            |
| Clarus Ventures I Management, L.P.<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142 |               |           |         |       | General Partner             |                            |
| Clarus Ventures I, LLC<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142             |               |           |         |       | GP Clarus Ventures I Mngmt. |                            |
| GALAKATOS NICHOLAS<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                 |               |           |         |       | Managing dir. of GP         |                            |
| HENNER DENNIS<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                      |               |           |         |       | Managing dir. of GP         |                            |
| LIPTAK ROBERT<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                      |               |           |         |       | Managing dir. of GP         |                            |
| Simon Nicholas<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210  |               |           |         |       | Managing dir. of GP         |                            |

CAMBRIDGE, MA 02142

STEINMETZ MICHAEL  
C/O CLARUS VENTURES, LLC  
101 MAIN STREET, SUITE 1210  
CAMBRIDGE, MA 02142

Managing dir. of GP

WHEELER KURT  
C/O CLARUS VENTURES, LLC  
101 MAIN STREET, SUITE 1210  
CAMBRIDGE, MA 02142

Managing dir. of GP

## Signatures

/s/ Robert Liptak, Managing director of Clarus Ventures I, LLC, general partner of Clarus Ventures I Management, L.P., general partner of Clarus Lifesciences I, L.P. 09/04/2013

\_\_Signature of Reporting Person Date

Robert Liptak, Managing director of Clarus Ventures I, LLC, general partner of Clarus Ventures I Management, L.P. 09/04/2013

\_\_Signature of Reporting Person Date

Robert Liptak, Managing director of Clarus Ventures I, LLC 09/04/2013

\_\_Signature of Reporting Person Date

Robert Liptak, as attorney-in-fact for Nicholas Galakatos 09/04/2013

\_\_Signature of Reporting Person Date

Robert Liptak, as attorney-in-fact for Dennis Henner 09/04/2013

\_\_Signature of Reporting Person Date

Robert Liptak 09/04/2013

\_\_Signature of Reporting Person Date

Robert Liptak, as attorney-in-fact for Nicholas Simon 09/04/2013

\_\_Signature of Reporting Person Date

Robert Liptak, as attorney-in-fact for Michael Steinmetz 09/04/2013

\_\_Signature of Reporting Person Date

Robert Liptak, as attorney-in-fact for Kurt Wheeler 09/04/2013

\_\_Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Distribution of shares in kind by Clarus Lifesciences I, L.P. (the "Fund") to its partners.

Clarus Ventures I Management, L.P. ("Clarus I Management") as the sole general partner of the Fund and Clarus Ventures I, LLC ("Clarus I GPLLC") as the sole general partner of Clarus I Management, may be deemed to beneficially own certain of the shares held of record by the Fund. Clarus I Management disclaims beneficial ownership of all shares held of record by the Fund in which Clarus I

(2) Management does not have an actual pecuniary interest. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of Clarus I GPLLC, may be deemed to beneficially own certain of the shares held of record by the Fund. Each of Clarus I GPLLC and Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by the Fund in which he does not have an actual pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

## Edgar Filing: STEINMETZ MICHAEL - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.